BOSTON--(BUSINESS WIRE)--Parthenon Therapeutics, a precision oncology company discovering and developing a novel class of therapies that reprogram the tumor microenvironment (TME), today announced ...
Immune exclusion, or the lack of immune cells in the vicinity of cancer cells, predicts poor patient outcomes in multiple cancers, including triple-negative breast cancer (TNBC). Now, researchers have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results